This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Nanotechnol. 2025, 16, 561–580, doi:10.3762/bjnano.16.44
Figure 1: Schematic representation of the hypothesized pathways leading to the formation of toxic amyloid-β o...
Figure 2: Illustration of calcium-mediated toxicity induced by oligomers. Oligomers initiate a calcium cascad...
Figure 3: This figure summarizes the key strategies discussed in our review for targeting AβOs in AD. Aβ mono...
Figure 4: This figure compares the inhibitory effects of Gln@CA-AuNP on HEWLO and HEWLF aggregation demonstra...
Figure 5: Illustration of the role of exosomes in transporting AβOs and tau protein, which are implicated in ...
Figure 6: Nanotechnological strategies for diagnosing, targeting, and imaging AβOs to halt the progression of...
Beilstein J. Nanotechnol. 2023, 14, 912–926, doi:10.3762/bjnano.14.75
Figure 1: Advantages of antibody-conjugated NPs.
Figure 2: Schematic representation of (a) an antibody and (b) targeted delivery via antibody-conjugated NPs.
Figure 3: Non-covalent antibody functionalization. (a) Drug-loaded NPs, (b) physical adsorption of antibodies...
Figure 4: Covalent antibody functionalization techniques. (a) Carbodimide coupling, (b) maleimide coupling, a...
Figure 5: Non-covalent antibody functionalization on NP surfaces using adaptor molecules (such as avidin or s...
Beilstein J. Nanotechnol. 2015, 6, 546–558, doi:10.3762/bjnano.6.57
Figure 1: (a) YVO4:Eu3+ NPs encapsulated with mesoporous silica NPs. The insets show SAED patterns of (b) YVO4...
Figure 2: MR image of mice liver (a) prior to and (b) 24 h after injection of the trimodal NPs. Reproduced wi...
Figure 3: Magnetic and luminescent properties of core–shell-type hybrid NPs, Fe3O4@CeF3:10%Tb3+/SiO2, (a,b) b...
Figure 4: Images of live HeLa cells after being incubated with Fe3O4/NaYF4 nanocomposites biolabeled with tra...